TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06618365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Deficiency
Description: The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Deficiency
Description: The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Deficiency
Description: The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Deficiency
Description: The first phase will involve studying 4 groups with the outcome (percentage of patients attaining Vitamin D levels \&gt;30ng/ml) at 3 months to show the superiority of any of the groups. Vitamin D levels will be checked at baseline then 6 and 12 weeks. The second phase will include only patients who achieve the target level above 30ng/ml after the first phase and will be randomized to receive either oral Vitamin D2 or oral Vitamin D3 every 2, 3 or 4 weeks for another 3 months.~For patients that achieved normal level in phase 1, we will keep a maintenance dose of the oral Vitamin D for 2 groups with 3 sub-groups under each.
Study: NCT06619145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose Oliceridine
Description: Low dose Oliceridine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose Oliceridine
Description: High dose Oliceridine
Study: NCT06620653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Patients assigned to the intervention group will receive a tablet (if the patients do not have a tablet, computer or smartphone), a weight scale and a blood pressure monitor. The patients will provide daily biometric data (weight, heart rate and blood pressure) and report symptoms through four questions to capture worsening symptoms of the cardiac condition.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: patients with a recent admission for heart failureare seen in a first face-to-face appointment within two weeks of discharge as per current 2021 ESC Heart Failure Guidelines with face-to-face follow up at 6 and 12 weeks.
Study: NCT06621953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BFR
Description: The intervention involves placing a pneumatic tourniquet system over the proximal thigh. The cuff is inflated to either 80% or 40% of limb occlusion pressure during lower limb strengthening exercises, as determined by Phase One (2318/MODREC/24a). These exercises include leg press and knee extensor exercises. Four sets (30,15,15,15 repetitions) performed at 20% of one repetition maximum in Week 1, 25% in Week 2 and 30% in Week 3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Standard residential rehabilitation consists of; (1) exercise-based therapy delivered in group settings and individually to address a variety of physical components relating to their pathology (e.g., balance and co-ordination, cardiovascular endurance, mobility and flexibility, motor control and dynamic stability, and muscular strength), (2) patient education sessions (e.g., activity modification, behavioural change, and focusing on pain management), and (3) one-on-one support sessions (e.g., dietetics, occupational therapy, physiotherapy, podiatry, prosthesis/orthosis specialists, social workers, and speech and language therapists).
Study: NCT06622525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: This group will receive 100 mEq of sodium bicarbonate diluted in one liter of saline solution, administered at a rate of 100 ml/h, with the goal of maintaining a urinary pH greater than 6.5.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No intervention
Description: The usual management for heat stroke will be given to this group
Study: NCT06731140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retinoic Acid
Description: Retinoic acid 20mg tid, p.o.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-PD-1 antibody and chemotherapy
Description: PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
Study: NCT05948124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-carnitine
Description: L-carnitine supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: Intravenous 5 ml of isotonic saline
Study: NCT05914831

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultra-fractionated WBI
Description: An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the whole breast where the tumor was located.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Ultra-fractionated PBI
Description: An ultra-short course of radiotherapy with 26Gy in 5 fractions will be administered to the part of the breast where the tumor was located.
Study: NCT05938725

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 anti-CD19 CAR-T cell therapy
Description: KYV-101 anti-CD19 CAR-T cell therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KYV-101 anti-CD19 CAR-T cell therapy
Description: KYV-101 anti-CD19 CAR-T cell therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard lymphodepletion regimen
Description: Standard lymphodepletion regimen
Study: NCT05918315

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal mucosa substitution urethroplasty
Description: Use of buccal mucosa as a substitution for urethroplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Buccal mucosa substitution urethroplasty
Description: Use of buccal mucosa as a substitution for urethroplasty
Study: NCT05589584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N acetyl cysteine with weight reduction
Description: high dose 2400mg/day
Study: NCT04728217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efmoroctocog Alfa Injection [Eloctate]
Description: Efmoroctocog alfa should be administered according to Summary of Product Characteristics (SmPC)/ Instruction on Medical Use approved by Russian Ministry of Health ЛП-006034 (13.01.2020).
Study: NCT06726902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GBT and SI with erythritol powder
Description: Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy~   * Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system.~  * Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with erythritol powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GBT and SI with glycine powder
Description: Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with glycine powder.~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GBT and SI with trehalose powder
Description: Non-Surgical Periodontal treatment:~1. Guided Biofilm Therapy • Guided supragingival and shallow subgingival (PD ≥ 4 mm) removal of biofilm and stains from all quadrants using the air-polishing device using a standard nozzle system. • Subgingival removal of biofilm from deeper periodontal pockets (PD ≥ 6 mm) using an Air-polishing device subgingival nozzle system with trehalose powder .~2. Scaling and root planing Scaling and root planing (SRP) For the control group, conventional scaling and root planning (SRP) only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SRP and SI
Description: conventional scaling and root planning (SRP) with subgingival instrumentation only will be performed
Study: NCT06406634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab
Description: Injectable solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: capsule
Study: NCT04985175

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Question prompt list
Description: The specific QPS was a one page leaflet for chronic kidney disease which developed by applied literature and public QPL from the National Health Agency. It contains 3 domains 25 questions related to treatment, dialysis, and Kidney transplant. The QPL group participants were asked to read and mark those questions they concerned or write down additional problems.
Study: NCT05754658

Intervention type: OTHER
Intervention: Standard of Care
Description: Drugs routinely administered for breast cancer per local standard.

Intervention type: OTHER
Intervention: Standard of Care
Description: Drugs routinely administered for prostate cancer per local standard.
Study: NCT06505161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: It consists in application of dry needling on active and/or latent TPs in low back multifidus muscles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous electrolysis
Description: It consists in the application of intratissue percutaneous electrolysis with galvanic current as a cathodic flow electrode in the low back multifidus muscles. The intervention will be guided by ultrasound equipment medically certified.
Study: NCT05818241

Intervention type: PROCEDURE
Intervention: Treatment of fracture by forearm cast
Description: Patient that are not surgically treated for DRF

Intervention type: PROCEDURE
Intervention: Surgical treatment of fracture
Description: Patients that are surgically treated for DRF
Study: NCT06276634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: During each AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the AIH intervention. The AIH intervention involves alternating breathing cycles: one with lower oxygen concentration (9-10% Oxygen) than that at sea level (\~21% Oxygen) lasting between 30 and 60 seconds, followed by a similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
Study: NCT05621369

Intervention type: BEHAVIORAL
Intervention: Participant self-assessment surveys
Description: At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.

Intervention type: BEHAVIORAL
Intervention: Participant self-assessment surveys
Description: At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.

Intervention type: BEHAVIORAL
Intervention: Participant self-assessment surveys
Description: At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.

Intervention type: BEHAVIORAL
Intervention: Psoriasis Draw
Description: Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.

Intervention type: BEHAVIORAL
Intervention: Psoriasis Draw
Description: Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.

Intervention type: BEHAVIORAL
Intervention: Psoriasis Draw
Description: Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.

Intervention type: BEHAVIORAL
Intervention: Psoriasis Area Photo
Description: Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
Study: NCT06327295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651-102- Cohort 1
Description: Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651-102- Cohort 2
Description: Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 once daily to the affected great toenail for 20 weeks with a follow-up for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651-102- Cohort 3
Description: Dosage form- Topical solution; Dosage- 3% formulation The participants will apply the daily dose of 3% ATB1651 twice daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.
Study: NCT06276634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham-Acute Intermittent Hypoxia
Description: During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham-Acute Intermittent Hypoxia
Description: During each Sham-AIH session, the participant will be equipped with a non-rebreathing face mask, and provided with the Sham-AIH intervention. The Sham-AIH intervention involves alternating breathing cycles: both with oxygen concentrations of \~21% Oxygen lasting between 30 and 60 seconds, followed by another similar duration of normal room air (21% Oxygen). This cycle will be repeated 15 times in one session, continuous blood oxygen levels and heart rate will be monitored.
Study: NCT06440733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program focused in elderly.
Description: Each of these sessions will be carried out taking into account the main physiotherapy objectives, such as gaining strength in both upper and lower limbs, as well as proprioception, balance, and promoting a pleasant and safe social environment where these older people feel valid.~All sessions will begin with a 5-minutes. It will begin with a general warm-up based on general joint mobility of the head and neck, shoulders, trunk, elbows, hands, wrists, hips, knees and ankles to begin to accustom the body to the physical work environment. And at the end of the sessions, a stretching program will be carried out, and it will end with a return to calm with a respiratory training program, in which you will be instructed to take in air through the nose and release it through the mouth, while the room is silent, and thus promote self-awareness.
Study: NCT06376591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Sucrosomial® B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Sucrosomial® B12

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vit B12
Description: Sucrosomial® B12

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: B-SUB® B12

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Mecogen SL® B12

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Evermin® B12

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vit B12
Description: Neuromax® B12
Study: NCT06355089

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Low-protein milk product
Study: NCT06327295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATB1651-102- Cohort 4
Description: Dosage form- Topical solution; Dosage- 5% formulation The participants will apply the daily dose of 5% ATB1651 once daily to the affected great toenail for 12 weeks with a follow-up for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will receive matching placebo across cohorts 1-4 of the study.
Study: NCT06355089

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein hydrolysate milk product
Description: Milk product with whey protein hydrolysate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Postbiotic and whey protein hydrolysate milk product
Description: Milk product with whey protein hydrolysate and Lacticaseibacillus rhamnosus GG
Study: NCT05760742

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MicAlgae
Description: 2 months of supplementation with an innovative microalgae based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MicAlgae
Description: 2 months of supplementation with an innovative microalgae based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MicAlgae
Description: 2 months of supplementation with an innovative microalgae based ingredient

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 months of supplementation with a placebo (Maltodextrin)
Study: NCT05864573

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZGGS15
Description: ZGGS15 for dose escalations are set as 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, and 30 mg/kg, intravenous infusion, once every 3 weeks.
Study: NCT06057519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Optimised dose rifampicin
Description: Optimized dose of rifampicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose rifampicin
Description: Standard dose rifampicin
Study: NCT05392621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A single Hatha yoga session designed to support stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A single Hatha yoga session designed to support stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A single Hatha yoga session designed to support stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: A single Hatha yoga session designed to support stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Breathing
Description: A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Breathing
Description: A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Breathing
Description: A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deep Breathing
Description: A single deep breathing exercise session designed to elicit relaxation and to assist in stress management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: A single session of progressive muscle relaxation designed to elicit relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: A single session of progressive muscle relaxation designed to elicit relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: A single session of progressive muscle relaxation designed to elicit relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: A single session of progressive muscle relaxation designed to elicit relaxation.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Quiet sitting
Description: A single session of quiet sitting.